FDA Must Reconsider Denial Of Braeburn Anti-Opioid Drug
A D.C. federal judge on Monday tossed a U.S. Food and Drug Administration decision that blocked a Braeburn Inc. drug that fights opioid-addiction from reaching the market, saying the agency needs...To view the full article, register now.
Already a subscriber? Click here to view full article